trending Market Intelligence /marketintelligence/en/news-insights/trending/m9mhp7on26udz0cw4upzaw2 content esgSubNav
In This List

Radius Health appoints chief medical officer

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Radius Health appoints chief medical officer

Waltham, Mass.-based biotechnology company Radius Health Inc. appointed Charles Morris as chief medical officer.

Morris was previously chief development officer at PsiOxus Therapeutics Ltd. He has also worked as the chief medical officer at Allos Therapeutics Inc., where he focused on the development of Folotyn in hematologic and solid tumors.

Jesper Hoiland, president and CEO of Radius Health, said that Morris' experience of late-stage drug trials and regulatory approvals will be vital during the phase 3 study of Elacestrant, or RAD1901, a treatment for breast cancer.

Radius Health develops hormone-based treatments for bone diseases and cancer.